{"disease":{"id":"alk-tki","name":"alk tki"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06643416","title":"Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Queen Mary Hospital, Hong Kong","has_results":false},{"nct_id":"NCT05178511","title":"Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Li Zhang, MD","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}